In a Phase II study reported in 2024 involving 168 patients with NASH, moderate to advanced fibrosis (F2F3), and NAS 4, a significantly greater proportion of patients in the denifanstat group achieved the primary endpoint compared with placebo, with statistically meaningful improvements in fibrosis as well
The FLOW trial was the first clinical trial that evaluated the effects of a GLP-1 medicine, semaglutide, on a composite outcome of progression of CKD and cardiovascular death, in people with T2D
Because a reduction in oxidative stress may help maintain cognitive status and/or prevent deterioration, the effects of vitamin E supplementation have been assessed in a few intervention studies
Most people begin losing weight on semaglutide within 24 weeks, with more noticeable and consistent weight loss typically occurring after 812 weeks, once doses are increased to therapeutic levels
About Ozempic Ozempic is the brand name for semaglutide, an antidiabetic medication that is primarily used for the treatment and management of type-2 diabetes
